First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Yaël C. Cohen, Hila Magen, Daniel Morillo et al.|Journal of Clinical Oncology|2023Cited by 88
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Suzette Girgis, Yang Chen et al.|Targeted Oncology|2023Cited by 46
S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDYFritz Offner, Jeffrey Matous, Olivier Decaux et al.|HemaSphere|2023Cited by 31
Teclistamab: Mechanism of action, clinical, and translational scienceYue Guo, Danièle Ouellet, Natalia A. Quijano Cardé et al.|Clinical and Translational Science|2024Cited by 29
S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)María‐Victoria Mateos, Hila Magen, Daniel Morillo et al.|HemaSphere|2023Cited by 9